Table 2.
Univariate and multivariate analyses of the association between baseline characteristics and survival in the clinical trial cohort.
| Variable | PFS | OS | ||
|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |
| HR (95% CI), P | HR (95% CI), P | HR (95% CI), P | HR (95% CI), P | |
| Age (≥60 vs <60) | 0.48 (0.24-0.95), P=0.036 | P=0.400 | 0.67(0.31-1.49), P=0.329 | – |
| Gender (female vs male) | 1.66 (0.78-3.56), P=0.191 | – | 1.58(0.63-3.98), P=0.328 | – |
| ECOG PS (1 vs 0) | 2.55 (1.20-5.44), P=0.015 | 2.39(1.03-5.51), P=0.042 | 1.91(0.83-4.41), P=0.128 | 2.52(1.00-6.32), P=0.049 |
| Liver metastasis (yes vs no) | 0.87 (0.45-1.69), P=0.688 | – | 0.75(0.35-1.64), P=0.478 | – |
| Peritoneum metastasis (yes vs no) | 1.14 (0.44-2.98), P=0.784 | – | 1.33(0.46-3.87), P=0.600 | – |
| Differentiation (poor vs moderation-well) | 1.48 (0.72-3.05), P=0.292 | P=0.620 | 1.63(0.72-3.69), P=0.241 | P=0.391 |
| History of operation (yes vs no) | 1.72 (0.69-4.27), P=0.241 | – | 2.09(0.78-5.59), P=0.144 | – |
| History of smoke (yes vs no) | 1.48 (0.70-3.18), P=0.312 | – | 1.32(0.52-3.32), P=0.556 | – |
| History of alcohol (yes vs no) | 1.17 (0.53-2.58), P=0.703 | – | 1.32(0.52-3.32), P=0.556 | – |
| NLR (≥3.85 vs <3.85) | 2.77 (1.35-5.69), P=0.005 | 2.59(1.20-5.61), P=0.016 | 2.66(1.21-5.82), P=0.015 | 3.35(1.42-7.91), P=0.006 |
| MLR (≥0.35 vs <0.35) | 2.64 (1.30-5.37), P=0.007 | P=0.760 | 2.11(0.96-4.68), P=0.065 | – |
| PLR (≥214.08 vs <214.08) | 2.30 (1.08-4.86), P=0.030 | P=0.742 | 1.66(0.72-3.85), P=0.238 | – |
| SII (≥1154.67 vs <1154.67) | 2.34 (1.07-5.14), P=0.034 | P=0.607 | 1.35(0.54-3.37), P=0.524 | – |
| dNLR (≥2.45 vs <2.45) | 1.91 (0.97-3.75), P=0.060 | – | 1.87(0.86-4.07), P=0.112 | – |
CI, confidence interval; dNLR, derived neutrophil-to-lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PLR, platelet-to-lymphocyte ratio; PFS, progression-free survival; SII, systemic immune-inflammation index.